Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure

Journal of Medicinal Chemistry

Volumn 59, Issue 16, 2016, Pages 7466-7477

  Schnapp, Gisela ^a   Klein, Thomas ^a   Hoevels, Yvette ^a   Bakker, Remko A ^a   Nar, Herbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN;

ARTICLE; BINDING KINETICS; COMPARATIVE STUDY; COVALENT BOND; DRUG STRUCTURE; ENTHALPY; ENTROPY; ISOTHERMAL TITRATION CALORIMETRY; SURFACE PLASMON RESONANCE; THERMODYNAMICS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; KINETICS; METABOLISM; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

BINDING SITES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; THERMODYNAMICS;

EID: 84983591619     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00475     Document Type: Article

References (49)

1. Kieffer, T. J.; McIntosh, C. H.; Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagonlike peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136, 3585-3596.
2. Meier, J. J.; Nauck, M. A.; Schmidt, W. E.; Gallwitz, B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul. Pept. 2002, 107, 1-13.
3. Egan, J. M.; Bulotta, A.; Hui, H.; Perfetti, R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes/Metab. Res. Rev. 2003, 19, 115-123.
4. Murphy, K. G.; Dhillo, W. S.; Bloom, S. R. Gut peptides in the regulation of food intake and energy homeostasis. Endocr. Rev. 2006, 27, 719-727.
5. McIntosh, C. H. Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front. Biosci., Landmark Ed. 2008, 13, 1753-1773.
6. Rasmussen, H. B.; Branner, S.; Wiberg, F. C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 2003, 10, 19-25.
7. Golightly, L. K.; Drayna, C. C.; McDermott, M. T. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin. Pharmacokinet. 2012, 51, 501-514.
8. Liu, Y.; Hu, Y.; Liu, T. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects. Curr. Med. Chem. 2012, 19, 3982-3999.
9. Nabeno, M.; Akahoshi, F.; Kishida, H.; Miyaguchi, I.; Tanaka, Y.; Ishii, S.; Kadowaki, T. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem. Biophys. Res. Commun. 2013, 434, 191-196.
10. Yoshida, T.; Akahoshi, F.; Sakashita, H.; Kitajima, H.; Nakamura, M.; Sonda, S.; Takeuchi, M.; Tanaka, Y.; Ueda, N.; Sekiguchi, S.; Ishige, T.; Shima, K.; Nabeno, M.; Abe, Y.; Anabuki, J.; Soejima, A.; Yoshida, K.; Takashina, Y.; Ishii, S.; Kiuchi, S.; Fukuda, S.; Tsutsumiuchi, R.; Kosaka, K.; Murozono, T.; Nakamaru, Y.; Utsumi, H.; Masutomi, N.; Kishida, H.; Miyaguchi, I.; Hayashi, Y. Discovery and preclinical profile of teneligliptin (3-[(2S, 4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl) piperazin-1-yl]pyrrolidin-2-y lcarbonyl]-thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. 2012, 20, 5705-5719.
11. Eckhardt, M.; Langkopf, E.; Mark, M.; Tadayyon, M.; Thomas, L.; Nar, H.; Pfrengle, W.; Guth, B.; Lotz, R.; Sieger, P.; Fuchs, H.; Himmelsbach, F. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2007, 50, 6450-6453.
12. Cusack, K. P.; Wang, Y.; Hoemann, M. Z.; Marjanovic, J.; Heym, R. G.; Vasudevan, A. Design strategies to address kinetics of drug binding and residence time. Bioorg. Med. Chem. Lett. 2015, 25, 2019-2027.
13. Andersson, K.; Karlsson, R.; Lofas, S.; Franklin, G.; Hamalainen, M. D. Label-free kinetic binding data as a decisive element in drug discovery. Expert Opin. Drug Discovery 2006, 1, 439-446.
14. Freire, E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discovery Today 2008, 13, 869-874.
15. Ladbury, J. E.; Klebe, G.; Freire, E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nat. Rev. Drug Discovery 2010, 9, 23-27.
16. Nunez, S.; Venhorst, J.; Kruse, C. G. Target-drug interactions: first principles and their application to drug discovery. Drug Discovery Today 2012, 17, 10-22.
17. Klebe, G. Applying thermodynamic profiling in lead finding and optimization. Nat. Rev. Drug Discovery 2015, 14, 95-110.
18. Liu, Y.; Hu, Y. Novel DPP-4 inhibitors against diabetes. Future Med. Chem. 2014, 6, 793-808.
19. Tummino, P. J.; Copeland, R. A. Residence time of receptorligand complexes and its effect on biological function. Biochemistry 2008, 47, 5481-5492.
20. Thomas, L.; Eckhardt, M.; Langkopf, E.; Tadayyon, M.; Himmelsbach, F.; Mark, M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther. 2008, 325, 175-182.
21. Pan, A. C.; Borhani, D. W.; Dror, R. O.; Shaw, D. E. Molecular determinants of drug-receptor binding kinetics. Drug Discovery Today 2013, 18, 667-673.
22. Wang, A.; Dorso, C.; Kopcho, L.; Locke, G.; Langish, R.; Harstad, E.; Shipkova, P.; Marcinkeviciene, J.; Hamann, L.; Kirby, M. S. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol. 2012, 12, 2.
23. Metzler, W. J.; Yanchunas, J.; Weigelt, C.; Kish, K.; Klei, H. E.; Xie, D.; Zhang, Y.; Corbett, M.; Tamura, J. K.; He, B.; Hamann, L. G.; Kirby, M. S.; Marcinkeviciene, J. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Protein Sci. 2008, 17, 240-250.
24. Schmidtke, P.; Luque, F. J.; Murray, J. B.; Barril, X. Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. J. Am. Chem. Soc. 2011, 133, 18903-18910.
25. Copeland, R. A. Conformational adaptation in drug-target interactions and residence time. Future Med. Chem. 2011, 3, 1491-1501.
26. Biela, A.; Nasief, N. N.; Betz, M.; Heine, A.; Hangauer, D.; Klebe, G. Dissecting the hydrophobic effect on the molecular level: the role of water, enthalpy, and entropy in ligand binding to thermolysin. Angew. Chem., Int. Ed. 2013, 52, 1822-1828.
27. Steuber, H.; Heine, A.; Klebe, G. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution. J. Mol. Biol. 2007, 368, 618-638.
28. Abel, R.; Young, T.; Farid, R.; Berne, B. J.; Friesner, R. A. Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. J. Am. Chem. Soc. 2008, 130, 2817-2831.
29. Young, T.; Abel, R.; Kim, B.; Berne, B. J.; Friesner, R. A. Motifs for molecular recognition exploiting hydrophobic enclosure in proteinligand binding. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 808-813.
30. Nguyen, C. N.; Cruz, A.; Gilson, M. K.; Kurtzman, T. Thermodynamics of Water in an Enzyme Active Site: Grid-Based Hydration Analysis of Coagulation Factor Xa. J. Chem. Theory Comput. 2014, 10, 2769-2780.
31. Nguyen, C. N.; Young, T. K.; Gilson, M. K. Grid inhomogeneous solvation theory: hydration structure and thermodynamics of the miniature receptor cucurbit[7]uril. J. Chem. Phys. 2012, 137, 044101.
32. Ruhmann, E.; Betz, M.; Fricke, M.; Heine, A.; Schafer, M.; Klebe, G. Thermodynamic signatures of fragment binding: Validation of direct versus displacement ITC titrations. Biochim. Biophys. Acta, Gen. Subj. 2015, 1850, 647-656.
33. Schuck, P.; Zhao, H. The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing. Methods Mol. Biol. 2010, 627, 15-54.
34. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discovery 2006, 5, 730-739.
35. Ferenczy, G. G.; Keseru, G. M. Thermodynamics guided lead discovery and optimization. Drug Discovery Today 2010, 15, 919-932.
36. Holdgate, G. A. Thermodynamics of binding interactions in the rational drug design process. Expert Opin. Drug Discovery 2007, 2, 1103-1114.
37. Swinney, D. C. The role of binding kinetics in therapeutically useful drug action. Curr. Opin. Drug Discovery Dev. 2009, 12, 31-39.
38. Englert, L.; Biela, A.; Zayed, M.; Heine, A.; Hangauer, D.; Klebe, G. Displacement of disordered water molecules from hydrophobic pocket creates enthalpic signature: binding of phosphonamidate to the S (1) '-pocket of thermolysin. Biochim. Biophys. Acta, Gen. Subj. 2010, 1800, 1192-1202.
39. Krimmer, S. G.; Betz, M.; Heine, A.; Klebe, G. Methyl, ethyl, propyl, butyl: futile but not for water, as the correlation of structure and thermodynamic signature shows in a congeneric series of thermolysin inhibitors. ChemMedChem 2014, 9, 833-846.
40. Scheen, A. J. A review of gliptins in 2011. Expert Opin. Pharmacother. 2012, 13, 81-99.
41. Scheen, A. J. A review of gliptins for 2014. Expert Opin. Pharmacother. 2015, 16, 43-62.
42. Graefe-Mody, U.; Retlich, S.; Friedrich, C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin. Pharmacokinet. 2012, 51, 411-427.
43. Fuchs, H.; Tillement, J. P.; Urien, S.; Greischel, A.; Roth, W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J. Pharm. Pharmacol. 2009, 61, 55-62.
44. Retlich, S.; Withopf, B.; Greischel, A.; Staab, A.; Jaehde, U.; Fuchs, H. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)-investigations in DPP-4 deficient and wildtype rats. Biopharm. Drug Dispos. 2009, 30, 422-436.
45. ∗). Diabetes, Obes. Metab. 2011, 13, 939-946.
46. Halabi, A.; Maatouk, H.; Siegler, K. E.; Faisst, N.; Lufft, V.; Klause, N. Pharmacokinetics of teneligliptin in subjects with renal impairment. Clin. Pharmacol. Drug Dev. 2013, 2, 246-254.
47. Retlich, S.; Duval, V.; Graefe-Mody, U.; Jaehde, U.; Staab, A. Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J. Clin. Pharmacol. 2010, 50, 873-885.
48. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-oxo-4-[3-(trifluoromethyl) - 5, 6-dihydro[1, 2, 4]triazolo[4, 3-a]pyrazin-7 (8H) - yl]-1-(2, 4, 5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 141-151.
49. Zhang, Z.; Wallace, M. B.; Feng, J.; Stafford, J. A.; Skene, R. J.; Shi, L.; Lee, B.; Aertgeerts, K.; Jennings, A.; Xu, R.; Kassel, D. B.; Kaldor, S. W.; Navre, M.; Webb, D. R.; Gwaltney, S. L. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J. Med. Chem. 2011, 54, 510-524.